Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$13.00 +2.9%	$11.42	$3.98 ▼ $13.40	$1.98B	1.92	2.17 million shs	1.95 million shs
DYN Dyne Therapeutics	$12.58 +2.9%	$10.23	$6.36 ▼ $46.81	$1.79B	1.08	3.08 million shs	2.30 million shs
MBX MBX Biosciences	$14.33 +1.3%	$12.51	$4.81 ▼ $27.50	$481.40M	N/A	328,877 shs	280,074 shs
VCEL Vericel	$37.03 +4.5%	$38.95	$33.09 ▼ $63.00	$1.87B	1.27	604,556 shs	758,535 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	0.00%	-0.31%	+21.95%	+45.58%	+182.00%
DYN Dyne Therapeutics	0.00%	+1.62%	+36.15%	+7.61%	-73.26%
MBX MBX Biosciences	0.00%	-2.65%	+9.98%	+17.94%	+1,432,999,900.00%
VCEL Vericel	0.00%	+2.07%	-6.77%	-9.51%	-23.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.4049 of 5 stars	1.4	1.0	4.2	2.0	1.7	0.6
DYN Dyne Therapeutics	3.4201 of 5 stars	4.5	1.0	0.0	2.7	4.2	0.0
MBX MBX Biosciences	1.9525 of 5 stars	3.5	0.0	0.0	1.1	1.7	0.6
VCEL Vericel	2.4884 of 5 stars	3.5	0.0	0.0	3.6	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.88	Moderate Buy	$12.38	-4.81% Downside
DYN Dyne Therapeutics	3.00	Buy	$33.80	168.68% Upside
MBX MBX Biosciences	3.00	Buy	$37.63	162.56% Upside
VCEL Vericel	3.00	Buy	$60.33	62.93% Upside

Current Analyst Ratings Breakdown

Latest MBX, ADPT, VCEL, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	ADPT Adaptive Biotechnologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $14.00
8/6/2025	ADPT Adaptive Biotechnologies	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
8/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$13.00 ➝ $15.00
8/6/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $13.00
8/5/2025	MBX MBX Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
8/1/2025	VCEL Vericel	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$61.00 ➝ $58.00
7/31/2025	DYN Dyne Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$66.00 ➝ $36.00
7/29/2025	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $23.00
7/29/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$37.00 ➝ $31.00
7/29/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $38.00
7/16/2025	MBX MBX Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	11.06	N/A	N/A	$1.18 per share	11.02
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$4.02 per share	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	$249.12M	7.50	$0.31 per share	118.50	$6.08 per share	6.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.82	N/A	N/A	N/A	-59.07%	-60.93%	-23.03%	11/6/2025 (Estimated)
DYN Dyne Therapeutics	-$317.42M	-$3.86	N/A	N/A	N/A	N/A	-64.12%	-56.75%	11/11/2025 (Estimated)
MBX MBX Biosciences	N/A	-$4.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	$10.36M	$0.12	308.61	84.16	N/A	2.85%	2.47%	1.69%	11/6/2025 (Estimated)

Latest MBX, ADPT, VCEL, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	-$0.17	+$0.07	-$0.17	$49.40 million	$49.94 million
7/31/2025	Q2 2025	VCEL Vericel	-$0.04	-$0.01	+$0.03	-$0.01	$64.61 million	$63.24 million
7/28/2025	Q2 2025	DYN Dyne Therapeutics	-$0.99	-$0.97	+$0.02	-$0.97	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.84	2.75
DYN Dyne Therapeutics	0.17	16.83	16.83
MBX MBX Biosciences	N/A	N/A	N/A
VCEL Vericel	N/A	4.97	4.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
DYN Dyne Therapeutics	96.68%
MBX MBX Biosciences	N/A
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
DYN Dyne Therapeutics	14.14%
MBX MBX Biosciences	52.19%
VCEL Vericel	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	152.27 million	142.53 million	Optionable
DYN Dyne Therapeutics	100	142.26 million	122.15 million	Optionable
MBX MBX Biosciences	36	33.59 million	N/A	N/A
VCEL Vericel	300	50.46 million	47.84 million	Optionable

MBX, ADPT, VCEL, and DYN Headlines

Recent News About These Companies

Analysts Set Vericel Corporation (NASDAQ:VCEL) PT at $60.33

August 24 at 2:13 AM | americanbankingnews.com

Vanguard Group Inc. Purchases 7,978 Shares of Vericel Corporation $VCEL

August 23 at 3:35 AM | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of "Buy" by Brokerages

August 23 at 3:24 AM | marketbeat.com

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 98,005 Shares of Vericel Corporation $VCEL

August 20, 2025 | marketbeat.com

Leerink Partners Raises the PT Vericel (VCEL), Maintains a Buy Rating

August 20, 2025 | msn.com

11 Best Small-Cap Growth Stocks to Buy Right Now

August 19, 2025 | insidermonkey.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Lord Abbett & CO. LLC

August 19, 2025 | marketbeat.com

Public Sector Pension Investment Board Grows Holdings in Vericel Corporation (NASDAQ:VCEL)

August 18, 2025 | marketbeat.com

Invesco Ltd. Acquires 35,345 Shares of Vericel Corporation (NASDAQ:VCEL)

August 18, 2025 | marketbeat.com

LPL Financial LLC Has $2.92 Million Holdings in Vericel Corporation (NASDAQ:VCEL)

August 18, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Stock Position Reduced by Neuberger Berman Group LLC

August 17, 2025 | marketbeat.com

Townsquare Capital LLC Purchases 7,312 Shares of Vericel Corporation (NASDAQ:VCEL)

August 13, 2025 | marketbeat.com

Vericel (VCEL) Receives a Buy from Canaccord Genuity

August 12, 2025 | theglobeandmail.com

Global Alpha Capital Management Ltd. Boosts Stock Holdings in Vericel Corporation (NASDAQ:VCEL)

August 10, 2025 | marketbeat.com

Zions Bancorporation National Association UT Makes New Investment in Vericel Corporation (NASDAQ:VCEL)

August 10, 2025 | marketbeat.com

CenterBook Partners LP Invests $888,000 in Vericel Corporation (NASDAQ:VCEL)

August 9, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Mutual of America Capital Management LLC

August 8, 2025 | marketbeat.com

Vericel Q2 Revenue Jumps 20%

August 5, 2025 | fool.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Geneva Capital Management LLC

August 4, 2025 | marketbeat.com

FY2025 EPS Estimates for Vericel Decreased by Analyst

August 4, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPS

August 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX, ADPT, VCEL, and DYN Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$13.00 +0.37 (+2.93%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$12.86 -0.14 (-1.08%)

As of 08/22/2025 07:35 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Dyne Therapeutics NASDAQ:DYN

$12.58 +0.36 (+2.95%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$12.58 0.00 (0.00%)

As of 08/22/2025 05:55 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

MBX Biosciences NYSE:MBX

$14.33 +0.18 (+1.27%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$14.34 +0.01 (+0.03%)

As of 08/22/2025 06:52 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Vericel NASDAQ:VCEL

$37.03 +1.59 (+4.49%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$37.03 +0.00 (+0.01%)

As of 08/22/2025 05:54 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time